[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
1. Kim SC, Natarajan-Ame S, Lioure B, Chenard MP, Duclos B, Herbrecht R, Bergerat JP: Successful treatment of a granulocytic sarcoma of the uterine cervix in complete remission at six-year follow-up. J Oncol; 2010;2010:812424

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a granulocytic sarcoma of the uterine cervix in complete remission at six-year follow-up.
  • Background. Localized granulocytic sarcoma of the uterine cervix in the absence of acute myelogenous leukemia (AML) at presentation is very rare, its diagnosis is often delayed, and its prognosis almost always ominous evolving into refractory AML. Case.
  • Further evaluation confirmed the presence of a granulocytic sarcoma but failed to reveal systemic involvement.
  • Results. AML type chemotherapy followed by radiotherapy of the uterus led to a durable complete remission.
  • She remains in complete remission six years after diagnosis.
  • Conclusion. Granulocytic sarcoma of the cervix is a rare entity for which early intensive AML type therapy is effective.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Intern Med J. 2006 Oct;36(10):669-71 [16958646.001]
  • [Cites] Gynecol Oncol. 2005 Sep;98(3):493-7 [16019058.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1156-65 [9331287.001]
  • [Cites] Nouv Rev Fr Hematol. 1995;37(5):273-6 [8700651.001]
  • [Cites] Int J Gynecol Cancer. 2004 May-Jun;14(3):553-7 [15228434.001]
  • [Cites] Br J Radiol. 1989 Nov;62(743):995-8 [2510900.001]
  • [Cites] J Clin Pathol. 1989 May;42(5):483-8 [2732341.001]
  • [Cites] Cancer. 1984 Apr 15;53(8):1764-6 [6582998.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Clin Lab Med. 1990 Dec;10(4):889-901 [2272180.001]
  • (PMID = 20454648.001).
  • [ISSN] 1687-8469
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2862322
  •  go-up   go-down


2. Mousavi A, Akhavan S: Sarcoma botryoides (embryonal rhabdomyosarcoma) of the uterine cervix in sisters. J Gynecol Oncol; 2010 Dec 30;21(4):273-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoma botryoides (embryonal rhabdomyosarcoma) of the uterine cervix in sisters.
  • Sarcoma botryoides (embryonal rhabdomyosarcoma) rarely arises in the uterine cervix.
  • We report a case of a 14-year-old female with sarcoma botryoides who presented with prolonged vaginal bleeding and cervical polyp.
  • The biopsy specimen confirmed sarcoma botryoides.
  • The patient underwent radical surgery of the tumor and hysterectomy without adjuvant chemotherapy.
  • The sister of the patient had died previously due to the same diagnosis at the age of 17.
  • Presence of sarcoma botryoides of the cervix in two sisters in the family highlights the possible role of genetic factors in the development of sarcoma botryoides.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 May;80(3-4):403-6 [10408845.001]
  • [Cites] Eur J Gynaecol Oncol. 2000;21(5):504-6 [11198044.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Aug;128(8):456-60 [12200603.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):742-8 [16214206.001]
  • [Cites] Obstet Gynecol Surv. 1986 May;41(5):257-63 [3517719.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):452-5 [14599884.001]
  • [Cites] Eur J Pediatr. 2004 Aug;163(8):452-6 [15173941.001]
  • [Cites] Gynecol Oncol. 1990 Jan;36(1):119-24 [2403958.001]
  • [Cites] Gynecol Oncol. 1988 Mar;29(3):290-304 [3278956.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):87-91 [8438559.001]
  • (PMID = 21278891.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3026308
  • [Keywords] NOTNLM ; Cervical cancer / Rhabdomyosarcoma / Sarcoma botryoides
  •  go-up   go-down


3. Nassar OA, Abdul Moaty SB, Khalil el-SA, El-Taher MM, El Najjar M: Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results. J Egypt Natl Canc Inst; 2010 Jun;22(2):113-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results.
  • PURPOSE: Uterine corpus sarcomas are rare heterogeneous tumors characterized by rapid progression and poor response to treatment.
  • This series investigated treatment options, relapse pattern, survival and prognostic factors.
  • Leiomyosarcoma accounted for 42.2% followed by carcinosarcoma (35.5%) and endometrial stromal sarcoma (18.6%).
  • Surgery was the primary line of treatment for all cases with total abdominal hysterectomy and bilateral salpingoophorectomy in 88% of cases and 12% had less extensive surgery.
  • Twenty-four (40.7%) patients had surgery alone, 24 (40.7%) had surgery and radiotherapy, 7 (11.9%) had surgery and chemo-irradiation and 4 (6.7%) had surgery and chemotherapy.
  • Stage, adjuvant irradiation, tumor size, myometrial invasion, vascular and cervix invasion were significant factors in univariate analysis; nevertheless, multivariate prognostic factors were only stage (p=0.04) and adjuvant irradiation (p=0.01).
  • Neither extent of surgery, chemotherapy, histologic type or grade had significant effect on survival.
  • Adjuvant radiotherapy offered 62% 2-year cumulative overall survival versus 22% for surgery alone and surgery with chemotherapy.
  • CONCLUSION: Diagnosis of uterine sarcoma is in itself a poor prognostic factor.
  • KEY WORDS: Uterine cancer - Uterine sarcoma - Uterine sarcoma treatment - Sarcoma irradiation - Sarcoma prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21860468.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


Advertisement
4. Virtanen A, Pukkala E, Auvinen A: Incidence of bone and soft tissue sarcoma after radiotherapy: a cohort study of 295,712 Finnish cancer patients. Int J Cancer; 2006 Feb 15;118(4):1017-21
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of bone and soft tissue sarcoma after radiotherapy: a cohort study of 295,712 Finnish cancer patients.
  • Radiotherapy is commonly used for treatment of malignant disease.
  • However, little is known about the effects of radiation on developing sarcoma.
  • The aim of this study was to examine the risk of developing a bone or soft tissue sarcoma after radiotherapy for a first primary cancer.
  • The study population included all the patients with primary cancers of breast, cervix uteri, corpus uteri, lung, ovary, prostate, rectum and lymphoma diagnosed during 1953-2000 and identified from the Finnish Cancer Registry.
  • Compared to the national incidence rates, after 10 years of follow-up sarcoma risk was increased among patients who had received neither radiotherapy nor chemotherapy (standardised incidence ratio (SIR) 2.0, 95% CI 1.3-3.0), radiotherapy without chemotherapy (SIR 3.2, 95% CI 2.3-4.3), chemotherapy without radiotherapy (SIR 4.9, 95% CI 1.0-14.4), as well as combined radiotherapy and chemotherapy (SIR 3.4, 95% CI 0.4-12.5).
  • In conclusion, radiotherapy appears to be associated with an increased risk of developing sarcoma especially among younger patients.
  • [MeSH-major] Bone Neoplasms / epidemiology. Bone Neoplasms / etiology. Neoplasms, Radiation-Induced / epidemiology. Osteosarcoma / epidemiology. Osteosarcoma / etiology. Sarcoma / epidemiology. Sarcoma / etiology


5. Bernal KL, Fahmy L, Remmenga S, Bridge J, Baker J: Embryonal rhabdomyosarcoma (sarcoma botryoides) of the cervix presenting as a cervical polyp treated with fertility-sparing surgery and adjuvant chemotherapy. Gynecol Oncol; 2004 Oct;95(1):243-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embryonal rhabdomyosarcoma (sarcoma botryoides) of the cervix presenting as a cervical polyp treated with fertility-sparing surgery and adjuvant chemotherapy.
  • BACKGROUND: Embryonal rhabdomyosarcoma (sarcoma botryoides) of the female genital tract is rare in the cervix.
  • It tends to occur in children and young women, and appears to have a better prognosis than sarcoma botryoides of the vagina and uterus.
  • CASE: We report a case of embryonal rhabdomyosarcoma (sarcoma botryoides) presenting as a cervical polyp in a 19-year-old female.
  • The patient was successfully treated with fertility-sparing surgery and adjuvant chemotherapy.
  • Therapy has recently inclined towards conservative treatment.
  • [MeSH-major] Polyps / diagnosis. Polyps / therapy. Rhabdomyosarcoma, Embryonal / diagnosis. Rhabdomyosarcoma, Embryonal / therapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Fertility. Humans


6. Blackwell KL, Kirkpatrick JP, Snyder SA, Broadwater G, Farrell F, Jolliffe L, Brizel DM, Dewhirst MW: Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin. Cancer Res; 2003 Oct 1;63(19):6162-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor oxygenation is known to be an important predictive/prognostic marker in a variety of tumors, including cervix, head/neck, sarcoma, non-small cell of the lung, and breast.
  • This study randomized 30 nonanemic, female Fischer 344 rats into three treatment arms to examine the effects of recombinant human erythropoietin (EPO) on R3230 rodent mammary carcinoma oxygenation.
  • The three treatment arms were: (a) placebo;.
  • On day 22, median tumor volume was 399 mm(3) (range: 65-950 mm(3)), and no differences in tumor volume were seen between treatment arms.
  • Mean hematocrit was equal between arms at therapy initiation but were significantly higher for both arms receiving EPO at day 22 (placebo versus Arm B versus Arm C; Wilcoxon P = 0.052).
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / drug therapy. Erythropoietin / pharmacology. Hemoglobins / metabolism. Mammary Neoplasms, Experimental / blood. Mammary Neoplasms, Experimental / drug therapy. Oxygen / blood

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14559797.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 40355
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; S88TT14065 / Oxygen
  •  go-up   go-down


7. Jeney H, Heller DS, Hameed M, Sama J, Cracchiolo B: Epithelioid sarcoma of the uterine cervix. Gynecol Oncol; 2003 Jun;89(3):536-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid sarcoma of the uterine cervix.
  • BACKGROUND: Epithelioid sarcoma is a rare, yet aggressive soft tissue neoplasm that has not previously been reported to originate in the cervix.
  • CASE: A 29-year-old woman was seen in consultation at our institution after having been diagnosed with a poorly differentiated carcinoma of the cervix, which was treated with radiation and chemotherapy.
  • Examination of the original biopsy material with additional studies led to a diagnosis of epithelioid sarcoma of the cervix.
  • CONCLUSION: Epithelioid sarcoma can occur in the cervix and should be included in the differential diagnosis of cervical neoplasms.
  • Additional cases are needed to develop optimum treatment strategies and predict prognosis.
  • [MeSH-major] Sarcoma / pathology. Uterine Cervical Neoplasms / pathology


8. Kanno S, Tomizawa A, Hiura T, Osanai Y, Shouji A, Ujibe M, Ohtake T, Kimura K, Ishikawa M: Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol Pharm Bull; 2005 Mar;28(3):527-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice.
  • We have investigated the effect of naringenin (NGEN) on tumor growth in various human cancer cell lines and sarcoma S-180-implanted mice.
  • NGEN showed cytotoxicity in cell lines derived from cancer of the breast (MCF-7, MDA-MB-231), stomach (KATOIII, MKN-7), liver (HepG2, Hep3B, Huh7), cervix (Hela, Hela-TG), pancreas (PK-1), and colon (Caco-2) as well as leukemia (HL-60, NALM-6, Jurkat, U937).
  • In vivo, NGEN inhibited tumor growth in sarcoma S-180-implanted mice, following intraperitoneal or peroral injection once a day for 5 d.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Flavanones / therapeutic use. Growth Inhibitors / pharmacology. Sarcoma 180 / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor / methods. Humans. Male. Mice

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744083.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Flavanones; 0 / Growth Inhibitors; HN5425SBF2 / naringenin
  •  go-up   go-down


9. Lee JW, Kim YT, Min YH, Kim JW, Kim SH, Park KH, Lim BJ, Yang WI: Granulocytic sarcoma of the uterine cervix. Int J Gynecol Cancer; 2004 May-Jun;14(3):553-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the uterine cervix.
  • Granulocytic sarcoma (GS) is a rare manifestation of leukemia and has been reported in 3-5% of acute myelogenous leukemia (AML) patients.
  • GS in the uterine cervix is very rare and is also called chloroma because of its greenish appearance.
  • We present the case of a patient whose disease relapsed as chloroma of the uterine cervix after bone marrow transplantation (BMT).
  • She was diagnosed as having chloroma by cervical smear and colposcopically directed biopsy of the cervix.
  • Systemic chemotherapy was administered on the presumption that myelogenous leukemia had recurred as chloroma, and a good clinical response was achieved.
  • We describe the first case of AML that relapsed as chloroma of the uterine cervix after complete remission of the AML, which had complete response to only systemic chemotherapy.
  • [MeSH-major] Leukemia, Myeloid, Acute. Sarcoma, Myeloid / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Diagnosis, Differential. Female. Humans


10. Li X, Liu L, Wu L: [Ifosfamide combination chemotherapy for advanced gynecologic malignancies]. Zhonghua Zhong Liu Za Zhi; 2000 Jul;22(4):330-2
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ifosfamide combination chemotherapy for advanced gynecologic malignancies].
  • OBJECTIVE: To evaluate the clinical efficacy and toxicity of ifosfamide (IFO) combination chemotherapy in patients with advanced gynecologic malignancies.
  • Of the 34 patients, 26 with epithelial cancer of the ovary were previously treated with cisplatin-containing combination chemotherapy but failed to respond or recurred after treatment.
  • The remaining 8 patients with uterine sarcoma (5 cases), squamous-cell carcinoma of the uterine cervix with metastases to the liver or bone (2 cases), and endometrial carcinoma with lung metastases (1 case) were treated with IFO combination chemotherapy.
  • At least two courses of treatment were given unless tumor progression occurred after the first course.
  • Two patients with cervical carcinoma and two of five patients with uterine sarcoma responded to IFO combination chemotherapy.
  • CONCLUSION: IFO combination chemotherapy is effective in treating recurrent or progressive gynecologic malignancies, especially PDD-sensitive ones.
  • Myelosuppression is relatively severe which may be due to prior long term and intensive chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ifosfamide / administration & dosage. Ovarian Neoplasms / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11778564.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


11. Saâdi I, Errihani H, Haddadi K, Amaoui B, Benjaafar B, El Gueddari BK: [Sarcoma botryoïde of the uterine cervix: report of a case]. Cancer Radiother; 2002 Dec;6(6):363-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sarcoma botryoïde of the uterine cervix: report of a case].
  • Botryoïde sarcoma of the uterine cervix is a very rare tumor of the young woman or during genial activity.
  • The treatment ranged from radical surgery to conservative surgery followed by chemotherapy.
  • We report a case of cervical botryoide rhabdomyosarcoma occurred in a 33 year-old woman treated primary by chemotherapy followed by surgery and adjuvant chemotherapy.
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12504774.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Scaravilli G, Simeone S, Dell'Aversana Orabona G, Capuano S, Serao M, Rossi R, Orabona P, Balbi C: Case report of a sarcoma botryoides of the uterine cervix in fertile age and literature review. Arch Gynecol Obstet; 2009 Nov;280(5):863-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report of a sarcoma botryoides of the uterine cervix in fertile age and literature review.
  • INTRODUCTION: The sarcoma botryoides of the cervix uteri occurs very rarely in fertile women.
  • CASE: Here is a case of a 35-year-old fertile woman, who developed a sarcoma botryoides of the cervix uteri.
  • The diagnosis required clinical examination, ecography, NMR, CT scan and a pathological examination of the surgical sample.
  • Radical surgery and chemotherapy was performed.
  • The patients is still living after more than 1 year after treatment.
  • DISCUSSION: Although the combined modality approach has given, if not constant, acceptable outcomes, a larger investigation on all the cases of sarcoma botryoides of the cervix uteri is expected.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Female. Histocytochemistry. Humans. Hysterectomy. Nuclear Magnetic Resonance, Biomolecular

  • Genetic Alliance. consumer health - Sarcoma botryoides.
  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19294398.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Zrara I, Mounzil CD, Rimani M, Bouzidi A, Labraimi A, Ben Omar C: [Botryoide sarcoma of the uterine cervix. Apropos of 1 case]. Gynecol Obstet Fertil; 2002 Oct;30(10):784-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Botryoide sarcoma of the uterine cervix. Apropos of 1 case].
  • Sarcoma botryoide (SB), a variant of rhabdomyosarcoma, is a rare tumor who are rarely localized in the uterine cervix.
  • The authors reported this case with review of the literature in order to insist on diagnosis progress and a new combined modality approach using: radiotherapy, surgery and chemotherapy which have improved prognosis in the localized disease especially.
  • [MeSH-major] Rhabdomyosarcoma / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Combined Modality Therapy. Desmin / analysis. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Immunohistochemistry. Ovariectomy. Prognosis. Radiotherapy. Vimentin / analysis

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12478984.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Desmin; 0 / Vimentin
  • [Number-of-references] 10
  •  go-up   go-down


14. Prados E, Garbin O, Kurtz JE: [Primary myeloid sarcoma of uterine cervix and prevention of fertility. Report of a case]. Gynecol Obstet Fertil; 2009 Mar;37(3):265-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary myeloid sarcoma of uterine cervix and prevention of fertility. Report of a case].
  • [Transliterated title] Traitement d'un sarcome myéloïde isolé du col utérin et préservation de la fertilité : à propos d'un cas.
  • The isolated myeloid sarcomas of the cervix are tumors whose forecast was dark for a long time.
  • However, an effective but invasive treatment associating chemotherapy and radiotherapy allows for local remission.
  • This treatment generally causes an ovarian failure and especially infertility.
  • We report the case of a 29-year-old woman suffering from a myeloid sarcoma isolated from the uterine cervix and wishing a pregnancy.
  • This patient presented normal menstrual cycles and a biochemical pregnancy three years after the beginning of the treatment.
  • [MeSH-major] Infertility, Female / prevention & control. Sarcoma, Myeloid / diagnosis. Uterine Cervical Neoplasms / diagnosis


15. Atlante M, Dionisi B, Cioni M, Di Ruzza D, Sedati P, Mariani L: Sarcoma botryoides of the uterine cervix in a young woman: a case report. Eur J Gynaecol Oncol; 2000;21(5):504-6
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoma botryoides of the uterine cervix in a young woman: a case report.
  • Among the rhabdomyosarcomas, which represent an uncommon neoplasm of mesoderm origin comprising about 1% of all female genital malignancies, sarcoma botryoides (SB) is an embrional variant usually found in the vagina of infants and young children under 16 years of age.
  • The onset of SB from the uterine cervix is very rare with a peak incidence in the second decade; only a few cases have been published in the international literature so far.
  • The authors report a case of embryonal rhabdomyosarcoma of the uterine cervix which occurred in a young woman treated by radical surgery, followed by adjuvant chemotherapy and radiotherapy.
  • [MeSH-major] Rhabdomyosarcoma, Embryonal / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Sarcoma botryoides.
  • Genetic Alliance. consumer health - Uterine sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11198044.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Miyamoto T, Shiozawa T, Nakamura T, Konishi I: Sarcoma botryoides of the uterine cervix in a 46-year-old woman: case report and literature review. Int J Gynecol Pathol; 2004 Jan;23(1):78-82
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoma botryoides of the uterine cervix in a 46-year-old woman: case report and literature review.
  • Sarcoma botryoides, which usually occurs in the vagina in childhood, is rare in the female reproductive tract of adult women, especially those over the age of 40.
  • We present a case of sarcoma botryoides of the uterine cervix that was an incidental finding in a 46-year-old woman.
  • Postoperative chemotherapy (vincristine and actinomycin D) was given according to the Intergroup Rhabdomyosarcoma Study protocol, and the patient was alive without recurrence 45 months postoperatively.
  • This is the only the fourth case reported in detail of a sarcoma botryoides of the uterine cervix in a patient over the age of 40.
  • [MeSH-minor] Age of Onset. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. MyoD Protein / metabolism. Myogenin / metabolism. Neoplasm Recurrence, Local. Polyps / pathology

  • Genetic Alliance. consumer health - Sarcoma botryoides.
  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14668557.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYOG protein, human; 0 / MyoD Protein; 0 / MyoD1 myogenic differentiation protein; 0 / Myogenin
  •  go-up   go-down


17. Kahlifa M, Buckstein R, Perez-Ordoñez B: Sarcomatoid variant of B-cell lymphoma of the uterine cervix. Int J Gynecol Pathol; 2003 Jul;22(3):289-93
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid variant of B-cell lymphoma of the uterine cervix.
  • A mass involving the uterine cervix and right parametrium was detected on pelvic examination and imaging studies.
  • A diagnosis of diffuse large B-cell lymphoma with a spindle-cell pattern was made with immunohistochemical and gene rearrangement studies on endocervical curettage and parametrial core biopsy specimens.
  • After chemotherapy and radiation therapy, the patient was in clinical and radiological remission 10 months after diagnosis.
  • To our knowledge, this is the first sarcomatoid B-cell lymphoma presenting in the uterine cervix.
  • Awareness of the spindle-cell pattern of diffuse large B-cell lymphoma and its possible presentation in extranodal sites such as the uterine cervix should prevent potential misdiagnosis.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Sarcoma. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Immunohistochemistry. Immunophenotyping. Menorrhagia. Pain. Prednisone / therapeutic use. Radiotherapy. Vincristine / therapeutic use. Weight Loss

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12819398.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


18. Farley J, O'Boyle JD, Heaton J, Remmenga S: Extraosseous Ewing sarcoma of the vagina. Obstet Gynecol; 2000 Nov;96(5 Pt 2):832-4
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraosseous Ewing sarcoma of the vagina.
  • BACKGROUND: Ewing sarcoma is a highly malignant childhood bone neoplasm.
  • Extraosseous presentations of Ewing sarcomas include the trunk, extremities, uterus, cervix, and vagina.
  • After surgical excision, pathology results diagnosed an extraosseous Ewing sarcoma.
  • Chemotherapy was given, followed by external beam and vaginal intracavitary brachytherapy, then more chemotherapy.
  • After 48 months post-treatment, there is no clinical evidence of recurrence.
  • CONCLUSION: Although rare, Ewing sarcoma can present as a vaginal mass.
  • [MeSH-major] Sarcoma, Ewing / pathology. Vaginal Neoplasms / pathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11094227.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


19. Behtash N, Mousavi A, Tehranian A, Khanafshar N, Hanjani P: Embryonal rhabdomyosarcoma of the uterine cervix: case report and review of the literature. Gynecol Oncol; 2003 Nov;91(2):452-5
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embryonal rhabdomyosarcoma of the uterine cervix: case report and review of the literature.
  • OBJECTIVES: Sarcoma botryoides rarely arises in the uterine cervix.
  • They were treated with two-stage surgical procedure and chemotherapy.
  • CONCLUSIONS: A combined modality approach to treating RMS using multidrug chemotherapy, radiotherapy, and surgery has markedly improved survival.
  • [MeSH-major] Rhabdomyosarcoma, Embryonal / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Humans

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14599884.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


20. Gastrell FH, Brasch HD, Johnson CA, Bethwaite PB, McConnell DT: Malignant mixed Müllerian tumour of the cervix treated with concurrent chemoradiation. Aust N Z J Obstet Gynaecol; 2001 Aug;41(3):352-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed Müllerian tumour of the cervix treated with concurrent chemoradiation.
  • Malignant mixed Müllerian tumours of the cervix are very uncommon.
  • Of the 26 cases reported in the literature only 8 consist of homologous sarcoma with squamous cell carcinoma.
  • Historically, treatment has been with radiation or surgery or a combination of both.
  • [MeSH-major] Mixed Tumor, Mullerian / drug therapy. Mixed Tumor, Mullerian / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11592561.001).
  • [ISSN] 0004-8666
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


21. Petković M, Zamolo G, Muhvić D, Coklo M, Stifter S, Antulov R: The first report of extraosseous Ewing's sarcoma in the rectovaginal septum. Tumori; 2002 Jul-Aug;88(4):345-6
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The first report of extraosseous Ewing's sarcoma in the rectovaginal septum.
  • AIMS AND BACKGROUND: To report an extremely rare case of Ewing's sarcoma located in the rectovaginal septum.
  • Ewing's sarcoma is a highly malignant neoplasm of bone, which usually occurs during childhood.
  • Common extraosseous localizations of Ewing's sarcoma include the trunk, extremities, uterus, cervix and vagina.
  • The mass had a size of 9 x 6 cm, a soft tissue consistency, was partially movable and the patient felt the pain during palpation.
  • Computed tomography (CT) showed an inhomogeneous expansive mass in the rectovaginal septum measuring 8.7 x 6.1 cm, without any signs of rectum or bladder invasion.
  • Immunohistology with the monoclonal antibody CD99 (MIC-2 gene product, Ewing's sarcoma marker, clone 12E7, DAKO A/S, Glostrup, Denmark) revealed an extraosseous Ewing's sarcoma.
  • The patient was treated with chemotherapy followed by whole-pelvis external beam radiation and intracavitary brachytherapy.
  • RESULTS: A residual mass measuring 3.5 x 2.5 cm was visible on a control CT scan 18 months after treatment; however, the patient was feeling well and refused surgery to remove the residual mass.
  • CONCLUSIONS: To our knowledge this is the first reported case of extraosseous Ewing's sarcoma in the rectovaginal septum.
  • [MeSH-major] Rectal Neoplasms / therapy. Sarcoma, Ewing / therapy. Vaginal Neoplasms / therapy

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12400989.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Snijders-Keilholz A, Ewing P, Seynaeve C, Burger CW: Primitive neuroectodermal tumor of the cervix uteri: a case report -- changing concepts in therapy. Gynecol Oncol; 2005 Sep;98(3):516-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumor of the cervix uteri: a case report -- changing concepts in therapy.
  • BACKGROUND: Peripheral primitive neuroectodermal tumor (PNET) of the cervix uteri is extremely rare.
  • The treatment policies in these eight cases differed considerably, partly due to the rarity of the disease and to differing time periods of diagnosis and treatment.
  • CASE: At the end of 2002, a 21-year-old woman presented with a PNET of the cervix uteri at our institute, the Erasmus Medical Center.
  • For the appropriate treatment in this case, we reviewed the literature and decided that the treatment should be different from the local surgical treatment followed by additional treatments as most of the earlier reports describe.
  • CONCLUSION: In view of the current knowledge of PNET belonging to the family of Ewing's sarcoma, and the improvement of treatment outcome in these tumors due to dose-intensive neo-adjuvant chemotherapy, patients with PNET of the cervix should be treated in accordance to the protocol for bony Ewing's sarcoma with multimodality therapy by means of induction chemotherapy, surgery, and consolidation chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neuroectodermal Tumors, Primitive, Peripheral / drug therapy. Neuroectodermal Tumors, Primitive, Peripheral / surgery. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Mesna / administration & dosage. Neoadjuvant Therapy. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15979131.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 9
  •  go-up   go-down


23. Toyoshima M, Okamura C, Niikura H, Ito K, Yaegashi N: Epithelioid leiomyosarcoma of the uterine cervix: a case report and review of the literature. Gynecol Oncol; 2005 Jun;97(3):957-60
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid leiomyosarcoma of the uterine cervix: a case report and review of the literature.
  • BACKGROUND: Epithelioid leiomyosarcomas arising from the uterine cervix are extremely rare neoplasms, with only three cases reported in the English literature.
  • Histological findings, including immunohistochemical study using desmin, SMA, cytokeratin, S-100, HMB-45, vimentin, melan-A, and CD68, led to a diagnosis of epithelioid leiomyosarcoma of the uterine cervix.
  • The patient underwent adjuvant chemotherapy and has been disease-free for over 20 months.
  • CONCLUSION: Immunohistochemical studies may be needed to differentiate among the alternative diagnoses of malignant melanoma, metastatic carcinoma, and epithelioid sarcoma.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890394.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


24. Park HM, Park MH, Kim YJ, Chun SH, Ahn JJ, Kim CI, Sung SH, Han WS, Kim SC: Mullerian adenosarcoma with sarcomatous overgrowth of the cervix presenting as cervical polyp: a case report and review of the literature. Int J Gynecol Cancer; 2004 Sep-Oct;14(5):1024-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mullerian adenosarcoma with sarcomatous overgrowth of the cervix presenting as cervical polyp: a case report and review of the literature.
  • An aggressive variant of adenosarcoma, mullerian adenosarcoma with sarcomatous overgrowth (MASO) in the cervix is extremely rare.
  • This variant contains obvious, high-grade sarcoma in addition to a low-grade form.
  • In this report, we describe a case of MASO of the uterine cervix and review the clinical and pathological features of these tumors.
  • The patient has been followed-up and neither chemotherapy nor other adjuvant therapies have been administered.
  • It is extremely rare that MASO of the uterine cervix is presented in premenopausal woman.
  • Gynecologists and pathologists should be aware of the difficulties associated with a delay in the diagnosis of MASO when the tumor is present as a benign looking cervical polyp.
  • [MeSH-minor] Adult. Diagnosis, Differential. Disease-Free Survival. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Ovariectomy


25. Karakousis CP: Surgical treatment of locally progressive stage IIIB carcinoma of the cervix: use of the inverted "T" incision. Eur J Obstet Gynecol Reprod Biol; 2004 Aug 10;115(2):216-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of locally progressive stage IIIB carcinoma of the cervix: use of the inverted "T" incision.
  • Stage III carcinoma of the cervix is treated usually, and often effectively, with the combination of radiation and chemotherapy.
  • The described surgical technique derives from soft tissue sarcoma pelvic surgery.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15262359.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 7
  •  go-up   go-down


26. Gruessner SE, Omwandho CO, Dreyer T, Blütters-Sawatzki R, Reiter A, Tinneberg HR, Bohle RM: Management of stage I cervical sarcoma botryoides in childhood and adolescence. Eur J Pediatr; 2004 Aug;163(8):452-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of stage I cervical sarcoma botryoides in childhood and adolescence.
  • Rhabdomyosarcomas are the most common soft tissue sarcomas in childhood.
  • The botryoid variant arises in infancy from the vagina or urinary bladder and extremely rarely from the uterine cervix.
  • Treatment regimes range from local excision of the tumour to radical hysterectomy with adjuvant multidrug therapy and/or radiotherapy.
  • In cases of minimal cervical invasion, the less invasive local excision in combination with adjuvant chemotherapy has resulted in excellent survival rates with complete functional preservation of the bladder, rectum, vagina, and ovaries.
  • We present here a 30-year literature review and a case report of a cervical sarcoma botryoides in a 5-year-old girl.
  • CONCLUSION: based on the literature review and our own observation, we recommend minor surgical approaches in combination with chemotherapy as the treatment of choice for early stage I cervical rhabdomyosarcoma.
  • [MeSH-major] Rhabdomyosarcoma, Embryonal / pathology. Rhabdomyosarcoma, Embryonal / therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Child, Preschool. Dactinomycin / therapeutic use. Female. Humans. Ifosfamide / therapeutic use. Neoplasm Staging. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Sarcoma botryoides.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Springer-Verlag
  • [Cites] Eur J Cancer. 2001 Apr;37(6):767-74 [11311652.001]
  • [Cites] Surg Clin North Am. 2000 Apr;80(2):747-60, xii [10836015.001]
  • [Cites] Obstet Gynecol. 1975 Feb;45(2):175-80 [1090863.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1552-60 [3621128.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jun;176(6):1563-9 [11373233.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2003 Feb;17(1):149-68 [12758232.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(2):112-20 [12806368.001]
  • [Cites] Cancer. 1975 Mar;35(3):677-86 [1111936.001]
  • [Cites] Eur J Gynaecol Oncol. 2000;21(5):499-500 [11198042.001]
  • [Cites] J Pediatr Surg. 1985 Dec;20(6):718-24 [3910785.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] Cancer. 2003 May 15;97(10):2597-604 [12733159.001]
  • [Cites] Eur J Gynaecol Oncol. 1996;17(5):335-7 [8933824.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):102-6 [9345364.001]
  • [Cites] J Surg Oncol. 2001 May;77(1):65-71 [11344486.001]
  • [Cites] Med Pediatr Oncol. 2003 Jul;41(1):1-6 [12764734.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2427-34 [10856103.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Jun;25(6):448-52 [12794522.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1050-62 [9849454.001]
  • [Cites] Ann N Y Acad Sci. 1967 May 10;142(3):694-708 [5231254.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Am J Surg. 2002 Dec;184(6):484-91 [12488143.001]
  • [Cites] Med Pediatr Oncol. 2001 Apr;36(4):481-8 [11260572.001]
  • [Cites] Gynecol Oncol. 1990 Jan;36(1):119-24 [2403958.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] J Pediatr Surg. 1999 May;34(5):731-4; discussion 734-5 [10359173.001]
  • [Cites] Obstet Gynecol. 1985 Aug;66(2):262-6 [3839576.001]
  • [Cites] Arch Dis Child. 2003 Apr;88(4):354-7 [12651771.001]
  • [Cites] Cancer. 1973 Dec;32(6):1310-6 [4202189.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2117-22 [10561266.001]
  • (PMID = 15173941.001).
  • [ISSN] 0340-6199
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 32
  •  go-up   go-down


27. Garcia MG, Deavers MT, Knoblock RJ, Chen W, Tsimberidou AM, Manning JT Jr, Medeiros LJ: Myeloid sarcoma involving the gynecologic tract: a report of 11 cases and review of the literature. Am J Clin Pathol; 2006 May;125(5):783-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid sarcoma involving the gynecologic tract: a report of 11 cases and review of the literature.
  • Myeloid sarcoma can involve any anatomic site, but involvement of the gynecologic tract is uncommon.
  • We describe 11 women, 17 to 60 years old, with myeloid sarcoma involving the gynecologic tract, including 5 patients in whom myeloid sarcoma presented as an isolated mass.
  • The uterus was the most frequently involved anatomic site, in 8 patients (5 corpus, 3 cervix).
  • Following chemotherapy, complete remission and long-term survival were achieved in a subset of patients, as was particularly true for 2 patients (cases 8 and 10), with complete remission 12.5 and 31 years after diagnosis, respectively.
  • [MeSH-major] Genital Neoplasms, Female / pathology. Sarcoma, Myeloid / pathology

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707383.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.11.1.7 / Peroxidase; EC 3.2.1.17 / Muramidase
  •  go-up   go-down


28. Mundhenke C, Bauerschlag D, Fischer D, Friedrich M, Maass N: [Malignant tumors of the uterus]. Ther Umsch; 2007 Jul;64(7):381-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Maligne Tumoren des Uterus.
  • Endometrial cancers are typically found in elderly women and are > 70% hormone sensitive (type I), type II is often less differentiated and not hormone sensitive.
  • Diagnosis can be achieved by vaginal ultrasound and by histology after hysteroscopy and curettage of the uterine cavity.
  • Therapy of choice is the stage related radical hysterectomy (incl. lymphnode dissection).
  • Postoperatively and at progressive stages endocrine and radiation therapies can be useful.
  • Chemotherapy is only useful in not hormone sensitive and in progressive tumors.
  • These often aggressive tumors are hardly responding to systemic and radiation therapy.
  • Therefore radical tumor surgery plays the main therapeutic role.
  • [MeSH-major] Sarcoma. Uterine Neoplasms
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cervix Uteri / pathology. Combined Modality Therapy. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / epidemiology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Endometrium / pathology. Female. Humans. Hysterectomy. Hysteroscopy. Lymph Node Excision. Middle Aged. Neoplasm Staging. Postoperative Care. Risk Factors. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / surgery. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948755.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 36
  •  go-up   go-down


29. Mangino M, Schena FP: [Skin cancer in renal transplant recipients]. G Ital Nefrol; 2010 Sep-Oct;27 Suppl 50:S75-80
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kidney transplant is the best treatment option for renal failure.
  • Twenty years after transplantation, approximately 70% of patients on continuous immunosuppressive therapy present one or more tumor types.
  • Examples are herpes virus 8 (HHV8), implicated in Kaposi's sarcoma (KS), human papillomavirus (HPV), involved in squamous cell cancer of the skin, vulva, vagina and cervix, and Epstein-Barr virus (EBV), responsible for post-transplant lymphoproliferative disorder (PTLD).
  • The type of drug used for the induction and maintenance of immunosuppression and the duration of treatment influence both the incidence and the type of cancer.
  • It is estimated that sarcomas occur 40 to 250 times more frequently in transplant recipients and are the leading cause of death from skin cancer after transplantation.
  • The reduction or suspension of immunosuppressive therapy is the first step in the treatment of post-transplant KS.
  • The second approach is chemotherapy.
  • In conclusion, new strategies must be developed to reduce cancer mortality in transplant recipients while ensuring adequate immunosuppression to preserve the transplanted organ.
  • [MeSH-minor] Humans. Sarcoma, Kaposi / chemically induced

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20922700.001).
  • [ISSN] 0393-5590
  • [Journal-full-title] Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
  • [ISO-abbreviation] G Ital Nefrol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


30. Penn I: Post-transplant malignancy: the role of immunosuppression. Drug Saf; 2000 Aug;23(2):101-13
MedlinePlus Health Information. consumer health - Organ Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Instead, there is a higher frequency of some relatively rare tumours, including post-transplant lymphomas and lymphoproliferative disorders (PTLD), Kaposi's sarcoma (KS), renal carcinomas, in situ carcinomas of the uterine cervix, hepatobiliary carcinomas, anogenital carcinomas and various sarcomas (excluding KS).
  • As the immunosuppressed state per se and various potentially oncogenic viruses play a major role in causing these cancers, preventative measures include reducing immunosuppression to the lowest level compatible with good allograft function and prophylactic measures against certain virus infections.
  • In addition to conventional treatments (resection, radiation therapy, chemotherapy) patients may receive antiviral drugs, interferon-alpha and various other manipulations of the immune system.
  • A significant percentage of cases of PTLD and KS respond to reduction or cessation of immunosuppressive therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Nephrol. 1994;14(2):121-6 [8080004.001]
  • [Cites] Lancet. 1982 Aug 14;2(8294):381-2 [6124778.001]
  • [Cites] Oncogene. 1997 Oct 2;15(14):1737-40 [9349508.001]
  • [Cites] Transplantation. 1995 Dec 27;60(12):1485-91 [8545879.001]
  • [Cites] Clin Transplant. 1996 Oct;10(5):429-31 [8930456.001]
  • [Cites] Immunol Rev. 1992 Jun;127:147-55 [1506004.001]
  • [Cites] Transplant Proc. 1996 Apr;28(2):876-8 [8623443.001]
  • [Cites] Transplant Proc. 1993 Feb;25(1 Pt 2):1383-4 [8442150.001]
  • [Cites] Thorax. 1988 Aug;43(8):653-6 [3051511.001]
  • [Cites] Crit Rev Oncog. 1989;1(1):27-52 [2488123.001]
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1333-5 [7557890.001]
  • [Cites] Transplant Proc. 1969 Mar;1(1):106-12 [4944206.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):183-9 [7829213.001]
  • [Cites] Liver Transpl Surg. 1996 Sep;2(5):375-82 [9346679.001]
  • [Cites] Am J Obstet Gynecol. 1984 Oct 1;150(3):300-8 [6091459.001]
  • [Cites] Nephrol Dial Transplant. 1994;9(4):443-5 [8084464.001]
  • [Cites] Transplantation. 1988 Apr;45(4):719-27 [2833828.001]
  • [Cites] J Clin Microbiol. 1997 Jun;35(6):1612-5 [9163497.001]
  • [Cites] Clin Transplant. 1992;6(Spec):249-252 [21151749.001]
  • [Cites] Cancer. 1976 Feb;37(2):729-34 [766948.001]
  • [Cites] Transplant Sci. 1994 Sep;4(1):23-32 [7804694.001]
  • [Cites] Transplant Proc. 1999 Feb-Mar;31(1-2):1260-2 [10083562.001]
  • [Cites] Hum Exp Toxicol. 1995 Jan;14(1):98 [7748628.001]
  • [Cites] Transplantation. 1995 Jan 27;59(2):240-4 [7839447.001]
  • [Cites] Hematol Oncol Clin North Am. 1993 Apr;7(2):467-75 [8385662.001]
  • [Cites] Br J Plast Surg. 1994 Mar;47(2):86-9 [8149064.001]
  • [Cites] Lancet. 1984 Mar 17;1(8377):583-7 [6142304.001]
  • [Cites] Transplantation. 1998 Oct 15;66(7):851-6 [9798693.001]
  • [Cites] Ann Intern Med. 1997 Jun 1;126(11):882-5 [9163289.001]
  • [Cites] Transplant Sci. 1994 Sep;4(1):46-60 [7804697.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1181-5 [7700310.001]
  • [Cites] Immunol Rev. 1997 Jun;157:217-22 [9255632.001]
  • [Cites] J Invest Dermatol. 1997 May;108(5):708-11 [9129219.001]
  • [Cites] Lancet. 1989 Jul 22;2(8656):224-5 [2568556.001]
  • [Cites] Transplantation. 1990 Mar;49(3):506-9 [2316011.001]
  • [Cites] Am J Med. 1988 Feb;84(2):225-32 [3044069.001]
  • [Cites] Transplantation. 1998 Aug 27;66(4):493-9 [9734494.001]
  • [Cites] Am J Med. 1979 Nov;67(5):759-65 [159624.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1933-8 [7636533.001]
  • [Cites] Transplantation. 1995 Jan 15;59(1):135-8 [7839414.001]
  • [Cites] Liver Transpl Surg. 1998 Mar;4(2):146-51 [9516567.001]
  • [Cites] Transplantation. 1995 Feb 27;59(4):480-5 [7878750.001]
  • [Cites] Transplantation. 1997 Sep 15;64(5):669-73 [9311700.001]
  • [Cites] Transplantation. 1997 Jun 15;63(11):1691-4 [9197369.001]
  • [Cites] Ann Transplant. 1997;2(4):33-40 [9869877.001]
  • [Cites] Annu Rev Med. 1995;46:381-94 [7598473.001]
  • [Cites] Transplantation. 1998 Dec 27;66(12):1604-11 [9884246.001]
  • [Cites] Nature. 1986 Aug 7-13;322(6079):502-3 [3461283.001]
  • [Cites] Am J Surg. 1998 Sep;176(3):265-9 [9776156.001]
  • [Cites] Transplantation. 1997 May 15;63(9):1200-5 [9158009.001]
  • [Cites] Obstet Gynecol. 1975 Apr;45(4):359-64 [1091896.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1141-50 [9305716.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]
  • [Cites] Am J Med. 1985 Jan 21;78(1A):44-9 [3970040.001]
  • [Cites] Photochem Photobiol. 1986 Mar;43(3):257-62 [3703959.001]
  • [Cites] Transplantation. 1989 Mar;47(3):458-64 [2538015.001]
  • [Cites] Transplantation. 1985 Jan;39(1):23-5 [3880960.001]
  • [Cites] Br J Dermatol. 1985 Dec;113(6):723-9 [3913458.001]
  • [Cites] Springer Semin Immunopathol. 1998;20(3-4):343-55 [9870250.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] Transplant Sci. 1994 Sep;4(1):42-5 [7804696.001]
  • [Cites] Ann Transplant. 1997;2(4):28-32 [9869876.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1712-7 [8970360.001]
  • (PMID = 10945373.001).
  • [ISSN] 0114-5916
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 71
  •  go-up   go-down


31. Henes M, Nauth A, Staebler A, Becker S, Henes JC: Postmenopausal bleeding as first sign of an acute myelogenous leukaemia: A case report and review of the literature. Med Oncol; 2010 Sep;27(3):815-9
Hazardous Substances Data Bank. PHENPROCOUMON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Manual and colposcopic examination raised suspicion of a cervical carcinoma, but histopathology and cervical Pap smear altered the diagnosis to granulocytic sarcoma (GS), an extramedullary manifestation of AML.
  • The patient had a normal blood count 2 weeks prior to the examination, but at the time of presentation her leukocytes had risen to 116000/microl.
  • In this case, GS of the cervix was the first sign of the AML with simultaneous appearance of leukocytosis and peripheral blasts.
  • GS of the female genital tract is very rare and diagnosis is challenging, especially on the basis of the Pap smear.
  • [MeSH-major] Sarcoma, Myeloid / diagnosis. Uterine Cervical Neoplasms / diagnosis. Uterine Hemorrhage / etiology
  • [MeSH-minor] Aged, 80 and over. Anticoagulants / adverse effects. Anticoagulants / therapeutic use. Carcinoma / diagnosis. Colposcopy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Phenprocoumon / adverse effects. Phenprocoumon / therapeutic use. Pulmonary Embolism / etiology. Thrombophilia / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Bleeding.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1974 Nov;44(5):735-48 [4528975.001]
  • [Cites] Eur J Gynaecol Oncol. 1996;17(1):25-8 [8750511.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1156-65 [9331287.001]
  • [Cites] J Gynecol Obstet Biol Reprod (Paris). 1995;24(1):30-4 [7730563.001]
  • [Cites] Chin Med J (Engl). 1999 Sep;112(9):858-60 [11717962.001]
  • [Cites] Taiwan Yi Xue Hui Za Zhi. 1984 Jun;83(6):618-25 [6593431.001]
  • [Cites] Diagn Cytopathol. 2009 Jan;37(1):61-7 [18973127.001]
  • [Cites] Gynecol Oncol. 2005 Sep;98(3):484-9 [15992915.001]
  • [Cites] Cancer. 1978 Feb;41(2):687-91 [343911.001]
  • [Cites] Int J Gynecol Pathol. 1983;2(1):88-92 [6192105.001]
  • [Cites] Gynecol Oncol. 1992 Jul;46(1):128-37 [1634133.001]
  • [Cites] J Gynecol Obstet Biol Reprod (Paris). 1990;19(7):857-61 [2277168.001]
  • [Cites] Acta Cytol. 1982 Jan-Feb;26(1):55-60 [6461154.001]
  • [Cites] Yonsei Med J. 1980;21(1):36-42 [6943870.001]
  • [Cites] J Clin Pathol. 1989 May;42(5):483-8 [2732341.001]
  • [Cites] Gynecol Obstet Fertil. 2009 Mar;37(3):265-8 [19269209.001]
  • [Cites] Cancer. 1977 Dec;40(6):3030-7 [338140.001]
  • [Cites] Leuk Lymphoma. 2002 Nov;43(11):2151-3 [12533040.001]
  • [Cites] Arch Pathol Lab Med. 2003 Jan;127(1):e28-31 [12562291.001]
  • [Cites] Gynecol Oncol. 2005 Sep;98(3):493-7 [16019058.001]
  • [Cites] Am J Clin Pathol. 2006 May;125(5):783-90 [16707383.001]
  • [Cites] J Obstet Gynaecol Res. 1997 Jun;23 (3):261-6 [9255039.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2530-45 [6585265.001]
  • [Cites] Int J Gynecol Cancer. 2004 May-Jun;14(3):553-7 [15228434.001]
  • [Cites] Blood. 1973 Nov;42(5):721-8 [4518064.001]
  • (PMID = 19763918.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; Q08SIO485D / Phenprocoumon
  •  go-up   go-down


32. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S, Swiss HIV Cohort: Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst; 2005 Mar 16;97(6):425-32
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
  • BACKGROUND: Persons infected with human immunodeficiency virus (HIV) have an increased risk for several cancers, but the influences of behavioral risk factors, such as smoking and intravenous drug use, and highly active antiretroviral therapy (HAART) on cancer risk are not clear.
  • RESULTS: Highly elevated SIRs were confirmed in persons infected with HIV for Kaposi sarcoma (KS) (SIR = 192, 95% confidence interval [CI] = 170 to 217) and non-Hodgkin lymphoma (SIR = 76.4, 95% CI = 66.5 to 87.4).
  • Statistically significantly elevated SIRs were also observed for anal cancer (SIR = 33.4, 95% CI = 10.5 to 78.6); Hodgkin lymphoma (SIR = 17.3, 95% CI = 10.2 to 27.4); cancers of the cervix (SIR = 8.0, 95% CI = 2.9 to 17.4); liver (SIR = 7.0, 95% CI = 2.2 to 16.5); lip, mouth, and pharynx (SIR = 4.1, 95% CI = 2.1 to 7.4); trachea, lung, and bronchus (SIR = 3.2, 95% CI = 1.7 to 5.4); and skin, nonmelanomatous (SIR = 3.2, 95% CI = 2.2 to 4.5).
  • [MeSH-major] Antiretroviral Therapy, Highly Active. CD4-Positive T-Lymphocytes. HIV Infections / complications. HIV Infections / drug therapy. Neoplasms / epidemiology. Neoplasms / etiology. Smoking / adverse effects
  • [MeSH-minor] Adult. Aged. Cohort Studies. Confounding Factors (Epidemiology). Female. Humans. Incidence. Lymphocyte Count. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology. Male. Medical Record Linkage. Middle Aged. Odds Ratio. Papillomaviridae. Prospective Studies. Registries. Research Design. Risk Assessment. Risk Factors. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / virology. Switzerland / epidemiology. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2005 Mar 16;97(6):407-9 [15769998.001]
  • (PMID = 15770006.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


33. Sitas F, Parkin DM, Chirenje M, Stein L, Abratt R, Wabinga H: Part II: Cancer in Indigenous Africans--causes and control. Lancet Oncol; 2008 Aug;9(8):786-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the relative importance of many lifestyle factors is becoming better understood in developed countries, more work is needed to understand the importance of these factors in different African settings.
  • We argue that risks for several exposures related to certain cancers differ from the patterns seen in developed countries.
  • In this paper, we review the current knowledge of causes of some of the leading cancers in Africa, namely cancers of the cervix, breast, liver, prostate, stomach, bladder, and oesophagus, Kaposi's sarcoma, non-Hodgkin lymphoma, and tobacco-related cancers.
  • There are no comprehensive cancer-control programmes in Africa and provision of radiotherapy, chemotherapy, and palliation is inadequate.
  • Certain cost-effective interventions, such as tobacco control, provision of antiretroviral therapy, and malarial and bilharzial control, can cause substantial decreases in the burden of some of these cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672214.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 86
  •  go-up   go-down


34. Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, Russo A, Intrieri T, Vercelli M, Zambon P, Tagliabue G, Zanetti R, Federico M, Limina RM, Mangone L, De Lisi V, Stracci F, Ferretti S, Piffer S, Budroni M, Donato A, Giacomin A, Bellù F, Fusco M, Madeddu A, Vitarelli S, Tessandori R, Tumino R, Suligoi B, Franceschi S, Cancer and AIDS Registries Linkage (CARL) Study: Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer; 2009 Mar 10;100(5):840-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A record-linkage study was carried out between the Italian AIDS Registry and 24 Italian cancer registries to compare cancer excess among persons with HIV/AIDS (PWHA) before and after the introduction of highly active antiretroviral therapy (HAART) in 1996.
  • SIR for Kaposi sarcoma (KS) and non-Hodgkin lymphoma greatly decreased in 1997-2004 compared with 1986-1996, but high SIRs for KS persisted in the increasingly large fraction of PWHA who had an interval of <1 year between first HIV-positive test and AIDS diagnosis.
  • A significant excess of liver cancer (SIR=6.4) emerged in 1997-2004, whereas the SIRs for cancer of the cervix (41.5), anus (44.0), lung (4.1), brain (3.2), skin (non-melanoma, 1.8), Hodgkin lymphoma (20.7), myeloma (3.9), and non-AIDS-defining cancers (2.2) were similarly elevated in the two periods.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / epidemiology. Antiretroviral Therapy, Highly Active. Neoplasms / epidemiology. Neoplasms / etiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):94-100 [12838307.001]
  • [Cites] Lancet. 2009 Jan 10;373(9658):181-3 [18684500.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):377-80 [11317082.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] J Biomed Inform. 2001 Dec;34(6):387-95 [12198758.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):84-90 [14501799.001]
  • [Cites] Antivir Ther. 2004 Feb;9(1):13-22 [15040532.001]
  • [Cites] AIDS. 2004 Jan 2;18(1):109-13 [15090836.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 21;96(14):1070-6 [15265968.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Lancet. 1993 Feb 13;341(8842):441 [8094208.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Clin Infect Dis. 2005 Jul 1;41(1):124-6; author reply 126-7 [15937776.001]
  • [Cites] AIDS Care. 2006 May;18(4):376-8 [16809116.001]
  • [Cites] Epidemiol Prev. 2006 Jan-Feb;30(1 Suppl 2):8-10, 12-28, 30-101 passim [16826725.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Arch Intern Med. 2006 Aug 14-28;166(15):1632-41 [16908797.001]
  • [Cites] Eur J Cancer Prev. 2006 Dec;15(6):554-6 [17106339.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Eur J Cancer. 2007 Apr;43(6):1085-91 [17349785.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Clin Infect Dis. 2007 Aug 15;45(4):510-3 [17638204.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2117-23 [17764927.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636 [18354839.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):800-4 [18665172.001]
  • [Cites] AIDS. 2008 Oct 18;22(16):2135-41 [18832877.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):282-6 [18845959.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):505-7 [12888821.001]
  • (PMID = 19223894.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2653754
  • [Investigator] Zucchetto A; De Paoli A; Colamartini A; Autelitano M; Crocetti E; Marani E; Fiore AR; Tittarelli A; Rosso S; Rashid I; Donato F; Pezzarossi A; Sgargi P; La Rosa F; Franchini S; Zanier L; Cesaraccio R; Senatore G; Vercellino PC; Vittadello F; Contrino ML; Antonini S; Maspero S; La Rosa MG; Boros S; Salfa MC
  •  go-up   go-down


35. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF: Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol; 2006 Feb;17(2):581-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
  • Median times to first skin and nonskin malignancies were compared between treatments using a survival analysis.
  • At 5 yr, the median time to a first skin carcinoma was delayed (491 versus 1126 d; log-rank test, P = 0.007), and the risk for an event was significantly lower with SRL-ST therapy (relative risk SRL-ST to SRL-CsA-ST 0.346; 95% confidence interval 0.227 to 0.526; P < 0.001, intention-to-treat analysis).
  • Nonskin cancers included those of the lung, larynx, oropharynx, kidney, gastrointestinal tract, prostate, breast, thyroid, and cervix as well as glioma, liposarcoma, astrocytoma, leukemia, lymphoma, and Kaposi's sarcoma.
  • Patients who received SRL-based, calcineurin inhibitor-free therapy after CsA withdrawal at month 3 had a reduced incidence of both skin and nonskin malignancies at 5 yr after renal transplantation compared with those who received SRL therapy combined with CsA.
  • [MeSH-minor] Adult. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Follow-Up Studies. Humans. Incidence. Risk Assessment

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434506.001).
  • [ISSN] 1046-6673
  • [Journal-full-title] Journal of the American Society of Nephrology : JASN
  • [ISO-abbreviation] J. Am. Soc. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


36. Camacho LH: Clinical applications of retinoids in cancer medicine. J Biol Regul Homeost Agents; 2003 Jan-Mar;17(1):98-114
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The survival benefit provided to patients with acute promyelocytic leukemia (APL) after induction therapy with all-trans RA and the responses experienced by patients with cutaneous lesions from Kaposi's sarcoma and cutaneous T cell lymphoma treated with 9-cis RA and a selective rexinoid--bexarotene--respectively, led to their approval by the Food and Drug Administration during the last decade.
  • The toxicity and efficacy of retinoids administered in combination with other biological and cytotoxic agents have also been explored in patients with renal cell carcinoma, breast cancer, myelodysplasia, prostate, cervix, and other malignancies with a broad range of reported responses.
  • Further characterization of the molecular processes modulated by these agents will serve to better define their role in the prevention and treatment of human cancer and to tailor specific targeted therapies in combination with other compounds.
  • [MeSH-major] Neoplasms / drug therapy. Retinoids / therapeutic use
  • [MeSH-minor] Clinical Trials as Topic. Drug Resistance, Neoplasm. Humans. Receptors, Retinoic Acid / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12757024.001).
  • [ISSN] 0393-974X
  • [Journal-full-title] Journal of biological regulators and homeostatic agents
  • [ISO-abbreviation] J. Biol. Regul. Homeost. Agents
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Receptors, Retinoic Acid; 0 / Retinoids
  • [Number-of-references] 167
  •  go-up   go-down


37. Rigor BM Sr: Pelvic cancer pain. J Surg Oncol; 2000 Dec;75(4):280-300
MedlinePlus Health Information. consumer health - Pelvic Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pelvic cancer causes several types of pain, i.e., visceral, neuropathic, and somatic pain.
  • In 60% of patients with malignant disease of soft tissues, nerve trunk, and sacral invasion from carcinoma of the cervix, uterus, vagina, colon, rectum, and other tissues in women, and from penile, prostate, and colorectal carcinoma and sarcoma in men, they have neuropathic pain.
  • Pain of these types is managed by different modalities depending on the age of the patient, the expected life expectancy, availability of invasive and non-invasive pain control modalities, and the resources of the patient, community, and health care agencies.
  • [MeSH-minor] Afferent Pathways / physiology. Analgesia, Patient-Controlled. Analgesics, Opioid / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antineoplastic Agents / therapeutic use. Chronic Disease. Combined Modality Therapy. Drug Administration Routes. Female. Home Care Services. Humans. Hypogastric Plexus / physiopathology. Male. Nerve Block. Spinal Cord / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 11135274.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down


38. Polin SA, Ascher SM: The effect of tamoxifen on the genital tract. Cancer Imaging; 2008;8:135-45
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tamoxifen is a selective estrogen receptor modulator (SERM) that is widely used in the treatment of patients with breast cancer and for chemoprophylaxis in high risk women.
  • Tamoxifen results in a spectrum of abnormalities involving the genital tract, the most significant being an increased incidence of endometrial cancer and uterine sarcoma.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Female Urogenital Diseases / chemically induced. Female Urogenital Diseases / ultrasonography. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Aged. Cervix Uteri / drug effects. Cervix Uteri / ultrasonography. Chemotherapy, Adjuvant. Dose-Response Relationship, Drug. Drug Administration Schedule. Endosonography / methods. Female. Follow-Up Studies. Humans. Incidence. Magnetic Resonance Imaging / methods. Middle Aged. Ovary / drug effects. Ovary / ultrasonography. Risk Assessment. Vagina / drug effects. Vagina / ultrasonography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1999 Feb;52(2):83-8 [10396232.001]
  • [Cites] Breast Cancer Res Treat. 1999 Apr;54(3):255-60 [10445424.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):136-41 [10502440.001]
  • [Cites] Eur J Gynaecol Oncol. 2005;26(3):257-65 [15991522.001]
  • [Cites] Obstet Gynecol. 2006 Jun;107(6):1475-8 [16738185.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2050-4 [10561257.001]
  • [Cites] Radiology. 2000 Jan;214(1):29-38 [10644098.001]
  • [Cites] Drug Saf. 2000 Jan;22(1):1-11 [10647972.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):181-6 [10926800.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):800-10 [10951343.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3459-63 [11032585.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3464-70 [11032586.001]
  • [Cites] Lancet. 2000 Sep 9;356(9233):881-7 [11036892.001]
  • [Cites] Lancet. 2001 Jan 6;357(9249):65-6; author reply 67 [11197376.001]
  • [Cites] Lancet. 2001 Jan 6;357(9249):66-7 [11197379.001]
  • [Cites] Obstet Gynecol. 2001 May;97(5 Pt 2):855-66 [11336777.001]
  • [Cites] Radiology. 2001 Sep;220(3):765-73 [11526280.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):137-50; discussion 151-5 [12533649.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(3-4):258-68 [12807236.001]
  • [Cites] J Ultrasound Med. 2003 Nov;22(11):1173-9 [14620887.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):553-8 [14766247.001]
  • [Cites] Cancer Treat Rev. 2004 May;30(3):291-301 [15059652.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):328-35 [15099941.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):256-66 [15297160.001]
  • [Cites] Br Med J. 1971 Jan 16;1(5741):152-4 [5539422.001]
  • [Cites] Br Med J. 1977 May 21;1(6072):1351-2 [861624.001]
  • [Cites] J Ultrasound Med. 1996 Apr;15(4):285-8 [8683662.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):409-11 [8774648.001]
  • [Cites] Breast Cancer Res Treat. 1996;38(2):183-99 [8861837.001]
  • [Cites] Clin Obstet Gynecol. 1996 Sep;39(3):629-40 [8862888.001]
  • [Cites] Semin Roentgenol. 1996 Oct;31(4):288-98 [8896105.001]
  • [Cites] AJR Am J Roentgenol. 1997 Mar;168(3):657-61 [9057510.001]
  • [Cites] Gynecol Oncol. 1997 Mar;64(3):386-91 [9062139.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jul;169(1):145-9 [9207515.001]
  • [Cites] Gynecol Oncol. 1997 Aug;66(2):233-7 [9264568.001]
  • [Cites] N Engl J Med. 1997 Dec 18;337(25):1792-8 [9400035.001]
  • [Cites] Lancet. 1998 Jan 3;351(9095):36 [9433432.001]
  • [Cites] Lancet. 1998 Jan 17;351(9097):155-7 [9449866.001]
  • [Cites] Obstet Gynecol. 1998 Jan;91(1):40-4 [9464718.001]
  • [Cites] Int J Cancer. 1998 May 4;76(3):325-30 [9579567.001]
  • [Cites] Lancet. 1998 May 16;351(9114):1451-67 [9605801.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2018-24 [9626198.001]
  • [Cites] Am J Obstet Gynecol. 1998 Jun;178(6):1145-50 [9662294.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 [9747868.001]
  • [Cites] Int J Gynecol Pathol. 1998 Oct;17(4):302-11 [9785130.001]
  • [Cites] N Engl J Med. 1998 Nov 26;339(22):1609-18 [9828250.001]
  • [Cites] Diagn Cytopathol. 1998 Dec;19(6):417-22 [9839130.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):21-6 [10094875.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1488-92 [10334535.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jun;172(6):1513-20 [10350282.001]
  • [Cites] Obstet Gynecol. 1999 Jun;93(6):1004-8 [10362171.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):527-37 [8133536.001]
  • [Cites] Lancet. 1994 May 28;343(8909):1318-21 [7910323.001]
  • [Cites] Radiographics. 1994 May;14(3):483-92 [8066264.001]
  • [Cites] Am J Obstet Gynecol. 1994 Sep;171(3):722-8 [8092221.001]
  • [Cites] J Ultrasound Med. 1994 Feb;13(2):99-104 [7932969.001]
  • [Cites] J Clin Pathol. 1994 Sep;47(9):827-33 [7962652.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 1):410-4 [7835781.001]
  • [Cites] Obstet Gynecol Surv. 1994 Dec;49(12):823-9 [7885659.001]
  • [Cites] Am J Obstet Gynecol. 1995 May;172(5):1488-94 [7755059.001]
  • [Cites] Gynecol Oncol. 1995 Jul;58(1):86-91 [7789896.001]
  • [Cites] Radiographics. 1995 May;15(3):501-14; discussion 515-6 [7624559.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 20;87(18):1359-64 [7658496.001]
  • [Cites] J Ultrasound Med. 1995 Sep;14(9):685-8 [7500435.001]
  • [Cites] Oncology. 1981;38(5):281-5 [7266969.001]
  • [Cites] Acta Obstet Gynecol Scand. 1983;62(5):393-6 [6421082.001]
  • [Cites] Radiology. 1987 Feb;162(2):297-305 [3797641.001]
  • [Cites] Fertil Steril. 1989 Dec;52(6):924-9 [2531684.001]
  • [Cites] Am J Obstet Gynecol. 1990 Jul;163(1 Pt 1):119-23 [2197861.001]
  • [Cites] Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):47-52 [1986624.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 17;83(14):1013-7 [2072407.001]
  • [Cites] Radiology. 1991 Oct;181(1):95-106 [1887062.001]
  • [Cites] Gynecol Oncol. 1991 Aug;42(2):120-3 [1894169.001]
  • [Cites] Obstet Gynecol. 1992 Jan;79(1):111-6 [1727568.001]
  • [Cites] Am J Obstet Gynecol. 1992 Jan;166(1 Pt 1):167-8 [1733191.001]
  • [Cites] AJR Am J Roentgenol. 1993 Mar;160(3):533-8 [8430547.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):485-90 [8383191.001]
  • [Cites] AJR Am J Roentgenol. 1993 Apr;160(4):809-12 [8456669.001]
  • [Cites] Obstet Gynecol. 1993 May;81(5 ( Pt 1)):660-4 [8469450.001]
  • [Cites] Br J Obstet Gynaecol. 1993 Apr;100(4):386-8 [8494842.001]
  • [Cites] J Ultrasound Med. 1993 May;12(5):275-80 [8345555.001]
  • [Cites] Breast Cancer Res Treat. 1993;26(1):101-5 [8400318.001]
  • [Cites] J Comput Assist Tomogr. 1994 Jan-Feb;18(1):77-86 [8282890.001]
  • [Cites] Lancet. 1994 Feb 19;343(8895):448-52 [7905955.001]
  • [Cites] Gynecol Oncol. 1994 Feb;52(2):185-90 [8314137.001]
  • [Cites] Am J Obstet Gynecol. 1994 Feb;170(2):447-51 [8116695.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):620-1 [8123501.001]
  • [Cites] Ultrasound Obstet Gynecol. 1995 Aug;6(2):116-20 [8535913.001]
  • [Cites] Radiology. 1995 Dec;197(3):603-8 [7480726.001]
  • [Cites] Radiology. 1996 Jul;200(1):105-10 [8657895.001]
  • (PMID = 18603495.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 95
  • [Other-IDs] NLM/ PMC2482152
  •  go-up   go-down






Advertisement